Theodore E. Ziemann. Mr. Ziemann is Chairman and Chief Executive officer. He was re-appointed CEO in March, 2018. He has served as Chairman of our Board of Directors since March, 2000. He also served as Chairman and Chief Executive Officer from August, 2007 through November, 2012.

Mr. Ziemann has over 45 years of experience in the life science industry, leading large geographically disbursed teams across multiple disciplines, including general management, marketing, manufacturing and engineering in North and South America, Europe, and Asia. Mr. Ziemann served as President of the Health and Food Technologies business of Cargill, Inc., from May, 2000 through May, 2006. From 1990 to 1999, he led various global multifunctional divisions for Rhone-Poulenc, SA, the French life science and chemical company, where he served as Sr. Executive Vice President of the global Plant and Animal Health Sector from 1998 to 1999 (Acquired by Bayer AG (FWB: BAYN) and Sanofi SA (SNY)); President of Rhone-Poulenc Ag Company from 1996 to 1998; President of the global Fine Chemical Division from 1993 to 1996. (Acquired by Solvay SA (Euronext: SOLB)); and Sr. Vice President of Manufacturing, Engineering, Safety and Quality for North America from 1990 to 1993. He also served as a member of Rhone-Poulenc’s Senior Corporate Technology Council from 1990 to 1999. Mr. Ziemann led various global director level positions in manufacturing, marketing, and engineering for Monsanto Company (MON) from 1970 to 1990. Mr. Ziemann has a B.S. in Chemical Engineering from Iowa State University and an Executive M.B.A. from the University of Iowa.

Mr. Ziemann brings to our company deep global senior executive management experience in the life science industry, as well as strong strategic, manufacturing, technology development, quality management, and engineering expertise. This combined with his direct engagement and historical perspective of our company, make him especially qualified to serve on the board of directors and direct the company as CEO.

Mr. Doughty brings over 19 years of experience in the healthcare field to Armis Biopharma. He joined the company in 2016 as a consultant focused on market research, disease epidemiology and operational systems and processes and is progressing towards joining Armis as a full time COO. In 2012 Mr. Doughty founded Delta Force Group Inc., a consulting firm specializing in all aspects of business performance in both established firms and start-ups where he led teams of over 200 people responsible for sales, marketing, clinical research and operational functions.

Previously Mr. Doughty served as Vice President of Commercial Operations at Cardiovascular Systems Inc. (NASDAQ: CSII) (2007–2013), as Marketing Director at EKOS Inc. (2006–2007) which was purchased by BTG Interventional Medicine (LSE: BTG.L) for $180M, as National Marketing Manager at Fox Hollow Technologies (2005–2006) which was purchased by Medtronic, as Director of Sales Operations at Medtronic (NYSE: MDT) (2000–2005) and as a sales professional at Johnson & Johnson (NYSE: JNJ) (1998–2000). The total market value of the two start-up entities where he previously served (Fox Hollow Technologies & Cardiovascular Systems Inc.) that were pre-revenue and ultimately went public, reached over $1.8B in market cap during his work.

Mr. Doughty holds a B.S. in public administration (1985), a M.P.A. (1990) from Oakland University, and an M.B.A from Michigan State University (1997).

Mr. Coder brings over 30 years of experience in a variety of functional areas including executive leadership, business development, product development, finance, mergers & acquisitions, and turn-arounds. He is currently the President and co-founder of an e-commerce startup launched in 2014. He also provides consulting services related to strategic business and product development and serves as a Senior Executive Coach & Mentor for Prositions.

Previously Mr. Coder was the President, CEO, and a member of the Board of Directors for Mayline, a manufacturer and distributer of mid-market office furniture. Prior to this he served in a variety of executive positions with HNI (formally HON Industries) where as SBU Vice President he was responsible for two business units with revenue aggregating $700 million, where his team took a product from $25 million to $100 million in sales in five years. He also served as Vice President and Controller leading the finance department at HON with revenue of $1.2 billion. He was promoted to Director of Operations while maintaining his Controller responsibilities and was instrumental in executing the sale of this company. Mr. Coder has also chaired numerous local fund raising initiatives for the City of Hope research hospital out of Los Angeles and multiple campaigns for local non-profit agencies. In addition, he has served on numerous volunteer boards. Mr. Coder began his career as an auditor with Ernst & Whinney.

Mr. Coder received a B.S. in Industrial Administration from Iowa State University and is a certified public accountant.

Dr. Okumu brings over 20 years of pharmaceutical product development experience to Armis Biopharma. He joined the company as a Product Development Advisor in 2017 leveraging his experience with global pharmaceutical development of innovative drugs, antibiotics and drug device combination products. Prior to his work at Armis, Dr. Okumu was Vice President of the Proprietary Products division of Dr. Reddy’s Laboratories (NYSE: RDY) where he contributed to the development and approval of multiple innovative products. Previously Dr. Okumu served a Principal Scientist in the Diabetes Research Unit at Novo Nordisk (NYSE: NVO), and as Executive Director of Biopharmaceutical Research and Development at DURECT Corporation (NASDAQ: DRRX). Prior to this, Dr. Okumu was the Associate Director of Pharmaceutical Sciences at Optimer Pharmaceuticals (NASDAQ: OPTR) where he co-invented Fidaxomicin the only locally acting macrocyclic antibiotic approved by the FDA in the past 30 years. Based on this approval Optimer Pharmaceuticals was acquired by Cubist Pharmaceuticals (NASDAQ: CBST, 2013) for $535M which was acquired later by Merck (NYSE: MRK) for $9.5B. Dr. Okumu began his career at Genentech (NASDAQ: DNA) and at Aradigm (NASDAQ: ARDM). Dr. Okumu holds a Bachelor of Science degree in Chemistry from Antioch College (1991) and a Ph.D. in Pharmaceutical Chemistry from The University of Kansas (1996).

Mr. Ziemann has over 45 years of experience in the life-science industry, leading large geographically disbursed teams across multiple disciplines, including general management, marketing, manufacturing and engineering in North and South America, Europe, and Asia. Mr. Ziemann has served as Chairman of Armis Biopharma Board of Directors since 2000. Previously he served both as Chairman and Chief Executive Officer of Armis (2007-2012).

Prior to this Mr. Ziemann served as President of the Health and Food Technologies business of Cargill, Inc. (2000-2006). Before this he led various global multifunctional divisions for Rhone-Poulenc, SA, the French life science and chemical company; served as Sr. Executive Vice President of the Plant and Animal Health Sector (acquired by Bayer AG ( ETR:BAYN) and Sanofi SA (NYSE:SNY)); President of Rhone-Poulenc Ag Company; President of the global Fine Chemical Division (acquired by Solvay SA (EBR:SOLB)); Sr. Vice President of Manufacturing, Engineering, Safety and Quality for North America; and served as a member of Rhone-Poulenc’s Senior Corporate Technology Council (1990-1999). Previously Mr. Ziemann held various global director level positions in manufacturing, marketing, and engineering for Monsanto Company (NYSE:MON) (1970-1990).

Mr. Ziemann has a B.S. in Chemical Engineering from Iowa State University (1969) and an M.B.A. from the University of Iowa (1986).

Dr. Neas has been with Armis Biopharma since 1998 as a founder and creator of the company’s technology platform when the company was originally Chata Biosystems, Inc. Chata’s technology assets of a patented packaging system for chemical delivery to analytical instruments used in pharmaceutical quality assurance laboratories, have since been sold.

Previously Dr. Neas was the Director of R&D and Quality Assurance for Summit Biotechnology (1994-1997), a wholly owned subsidiary of ConAgra Corporation. Prior to this Dr. Neas served as part owner and Vice President of R&D at Rubbright Corporation, a small biotech consulting company (1983-1992). Before that Dr. Neas held the position of principal scientist and head of research involved in development of new products at CEM Corporation, now a large corporation developing microwave based technology for analytical chemistry. Dr. Neas began his career as Director of R&D for the development of new products at HyClone Laboratories (1981-1983) now owned by GE Healthcare Life Sciences and Thermo Scientific.

Dr. Neas received his bachelor and master’s degrees from Texas A&M, Kingsville Texas, in microbiology, with minors in chemistry, and his Ph.D. from Utah State University in microbiology. Dr. Neas is one of the inventors on eighteen issued patents, 24 pending applications, and 3 new Armis Biopharma provisional applications.

Mr. Litwack began his retailing career with a Federated department store, then to a May Co. store where he became one of the youngest divisional vice-presidents. Following that experience, Mr. Litwack joined one of the Midwest’s fastest growing women’s discount stores and wholesale companies, Gateway Apparel/Fashion Gal Stores, as a partner and vice-president of merchandising. After retiring at an early age, Mr. Litwack has been engaged in community volunteer work serving as Chairman, Board member and Executive committee member of non-profit organizations.

At the same time, he has been involved in a number of investment opportunities, particularly early developing companies, several of which have gone public, including Talx – acquired by Equifax, Jones Medical – acquired by Medicine Shoppe which was later acquired by Cardinal Health, Catalyst International, and Telecom Towers LP – which was later sold to American Towers. For the last twenty years, Mr. Litwack has been an active partner in a local chain of successful casual dining restaurants.

Mr. Litwack received a BS degree in Economics from the University of Wisconsin-Madison in 1959.

Dr. Nelson, a trained genitourinary medical oncologist, is a recognized leader in cancer research. Since 2008 he serves as the Marion I. Knott Director of the Sidney Kimmel Comprehensive Cancer Center (SKCCC) and the Department of Oncology the Johns Hopkins University School of Medicine. His research laboratory, focused on prostate cancer, discovered one of the first epigenetically-silenced human cancer genes which became the basis for assays marketed as adjunct cancer diagnostic tests by MDxHealth (MDXH; Brussels).

Dr. Nelson has authored more than 250 published works, garnered nearly 30,000 citations, been granted 10 patents, and earned several prizes and honors. He serves on the Board of the V Foundation, as a Scientific Co-Chair for Stand Up to Cancer, and on the Scientific Advisory Board for the Prostate Cancer Foundation. He is also the Executive Editor of Cancer Today. He has been a Member of the Cancer Scientific Advisory Council for AbbVie, Inc. (ABBV; NYSE) and the Scientific Advisory Board for ProQuest Investments, Inc. He serves as an ad hoc consultant for GlaxoSmithKline, Inc. (GSK; NYSE), Merck and Co. (MRK; NYSE), and Celgene (CELG; NASDAQ) and a Co-Founder and Medic al Advisory Board Member for Digital Harmonics.

Dr. Nelson completed his internal medicine residency and medical oncology fellowship training at the Johns Hopkins Hospital where he became Professor of Oncology, Urology, Pathology, Pharmacology, Medicine, Radiation Oncology, and Environmental Health Sciences (1992). Dr. Nelson earned a B.A. in Chemistry at Yale University in 1980, and both an M.D. and a Ph.D. in Pharmacology in from Johns Hopkins in 1987.

Alan J. Ruud serves as Chief Executive Officer and President of Kramer Lighting, Inc. A professional engineer and lighting designer, Mr. Ruud is nationally recognized for his expertise in the lighting industry. He founded Ruud Lighting, Inc. in 1982 and served as its Chairman and Chief Executive Officer.

Since 1999, he served as the President and Chief Operating Officer of Ruud Lighting, Inc. Previously Mr. Ruud founded and managed SPI Lighting, an HID lighting manufacturer (1973-1982), which was sold to McGraw Edison in 1978. He ran a consulting and lighting engineering group in Milwaukee, Wisconsin (1969-1979). Mr. Ruud served as Vice Chairman of Lighting at Cree, Inc. and as a Director (2011-2015). He has been on Board of the Milwaukee School of Engineering (MSOE) Board of Regents since 1990 and currently serves as the Chairman. In addition he serves as a Director of Fiberstars, Inc.

In addition to numerous patents for his innovative designs, he has received a number of awards including the Master Key to Success from MSOE in 1988 and was given an Honorary Doctor of Engineering degree from MSOE in 1998. Mr. Ruud received an M.B.A. from the University of Chicago.

Dr. Smith brings over 30 years of executive industry management in research and development, operations, manufacturing and quality roles to Armis Biopharma. He has served on our Board of Directors since it was formed in 1998. He joined Bellicum Pharmaceuticals Inc. (NASDAQ: BLCM), his current employer, in 2015 as Sr. Vice President, Manufacturing and currently serves as Executive Vice President of Technical Operations. Prior to this, he served as the Vice President of Research & Development and Cellular Therapeutics for LifeNet Health and its subsidiary, The Institute of Regenerative Medicine (2013-2015). Previously, Dr. Smith owned an independent consulting business in the cell therapy industry (2010-2013).

Before this he served as President and Chief Executive Officer and in other executive roles for Cognate BioServices (2002-2010); as Chief Operating Officer and Sr. Vice President of Research and Development at Osiris Therapeutics (NYSE: OSIR); as Vice President of Research and Development at Aastrom Biosciences; as Vice President of Research and Development Geneic Sciences at Baxter Healthcare Corporation (now Baxter International Inc., NYSE: BAX); and several other leadership positions in additional companies. Dr. Smith is a published co-author on numerous journal articles and recently served as an Adjunct Professor at Eastern Virginia Medical School, Department of Biology and Molecular Cell Biology.

His past academic experience includes adjunct professorships at California State University Long Beach and Utah, State University. Dr. Smith earned his BS degree in Chemistry at Southern Utah University in 1976 and a PhD degree in Biochemistry from Utah State University in 1982.

Ruud holds an executive master’s in business administration degree from Loyola University and received his Bachelor of Science degree in computer science and mathematics from Pepperdine University.

An active member of the Racine community, Ruud is President of the Ruud Family Foundation, serves on the board of advisors for Forward Racine, the board of directors for Pepperdine University and the board of directors and executive committee for The Prairie School.

Ruud was the President of Ruud Lighting which later was sold to Cree where Ruud became president of the lighting division and later became the head of Global LED Adoption. Ruud is also the CEO and majority owner in DeltaHawk Engines and The Attillio Group and an active investor in several other businesses around the country.

Chris is married with three children. Jacob, Zachary and Caitlyn definitely keep him busy with their sporting and extra curricular activities. Chris and his wife Chantil own and manage a business importing and training horses out of Ocala, FL in their spare time.

Chris’ favorite hobby is racing cars. Chris is a member of the Ferrari Corse Clienti group where he travels worldwide to drive some of his cars such as the Ferrari FXXK and the 333SP.